XOMA Royalty’s (XOMA) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of XOMA Royalty (NASDAQ:XOMA) in a report published on Friday morning,Weiss Ratings reports.

A number of other equities analysts have also recently issued reports on XOMA. Wall Street Zen raised shares of XOMA Royalty from a “hold” rating to a “buy” rating in a report on Monday, August 11th. Zacks Research cut shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, October 20th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $69.50.

XOMA Royalty Stock Performance

Shares of XOMA stock opened at $35.17 on Friday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.88 and a current ratio of 4.88. XOMA Royalty has a one year low of $18.35 and a one year high of $39.92. The company’s 50-day simple moving average is $35.82 and its 200-day simple moving average is $28.98. The stock has a market capitalization of $425.13 million, a price-to-earnings ratio of -22.69 and a beta of 1.02.

XOMA Royalty (NASDAQ:XOMA) last issued its earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.60. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%. The firm had revenue of $13.13 million for the quarter, compared to analysts’ expectations of $9.39 million. Equities analysts anticipate that XOMA Royalty will post -1.41 earnings per share for the current fiscal year.

Insider Buying and Selling at XOMA Royalty

In other news, CFO Thomas M. Burns sold 4,330 shares of XOMA Royalty stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $35.99, for a total transaction of $155,836.70. Following the sale, the chief financial officer owned 30,079 shares of the company’s stock, valued at approximately $1,082,543.21. The trade was a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 9.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC increased its stake in shares of XOMA Royalty by 203.1% during the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,523 shares during the period. Opaleye Management Inc. increased its stake in shares of XOMA Royalty by 0.8% during the second quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company’s stock valued at $6,428,000 after acquiring an additional 2,044 shares during the period. Raymond James Financial Inc. acquired a new position in shares of XOMA Royalty during the second quarter valued at approximately $116,000. Occudo Quantitative Strategies LP acquired a new position in shares of XOMA Royalty during the second quarter valued at approximately $527,000. Finally, Marshall Wace LLP increased its stake in shares of XOMA Royalty by 12.2% during the second quarter. Marshall Wace LLP now owns 16,308 shares of the biotechnology company’s stock valued at $411,000 after acquiring an additional 1,775 shares during the period. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.